Emerging drugs for the treatment of primary biliary cholangitis

References

• Hirschfield GM, Beuers U, Corpechot C, et al. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145–172.
   PubMed Web of Science ®Google Scholar
• Marschall H, Henriksson I, Lindberg S, et al. Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. Sci Rep. 2019;9:11525.
   PubMed Web of Science ®Google Scholar
• Shah RA, Kowdley KV. Current and potential treatment for primary biliary cholangitis. Lancet Gastroenterol Hepatol. 2020;5:306–315.
   PubMed Web of Science ®Google Scholar
• Lee JY, Danford CJ, Trivedi HD, et al. Treatment of fatigue in primary biliary cholangitis: a systematic review and meta-analysis. Dig Dis Sci. 2019 Aug;64:2338–2350.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UKPBC. Primary biliary cholangitis treatment and management guidelines. Gut. 2018;67:1568–1594.
   PubMed Web of Science ®Google Scholar
• Cordell HJ, Han Y, Mells GF, et al. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat Commun. 2015;6:8019.
   PubMed Web of Science ®Google Scholar
• Cheung AC, Lammers WJ, Murillo Perez CF, et al. Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis. Clin Gastroenterol Hepatol. 2019;17:2076.
   PubMed Web of Science ®Google Scholar
• Harms MH, de Veer RC, Lammers WJ, et al. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut. 2019 Dec 16. DOI:10.1136/gutjnl-2019-319057.
   PubMed Web of Science ®Google Scholar
• Carbone M, Nardi A, Flack S, et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA response score. Lancet Gastroenterol Hepatol. 2018;3:626–634.
   PubMed Web of Science ®Google Scholar
• Murillo Perez CF, Hirschfield GM, Corpechot C, et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment Pharmacol Ther. 2019;50:1127–1136.
   PubMed Web of Science ®Google Scholar
• Pellicciari, Fiorucci S, Camaioni E, et al. 6α-ethyl-chenodexoycholic acid (6-ECDCA),a potent and selective FXR agonist endowed with anticholestatitc activity. J Med Chem. 2002;45:3569–3572.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127:1497–1512.
   PubMed Web of Science ®Google Scholar
• Nevens F, Andreone P, Mazzela G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643.
   PubMed Web of Science ®Google Scholar
• Trauner M, Nevens F, Shiffman ML, et al. efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol. 2019;4:445–453.
   PubMed Web of Science ®Google Scholar
• Jones DE. Pathogenesis of cholestatic itch: old questions, new answers, and future opportunities. Hepatology. 2012;56:1194–1196.
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare products Regulatory Agency (MHRA). Obeticholic acid (Ocaliva): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring. cited 2020 Jan 7. Available from: https://www.gov.uk/drug-safety-update/obeticholic-acid-ocaliva-risk-of-serious-liver-injury-in-patients-with-pre-existing-moderate-or-severe-hepatic-impairment-reminder-to-adjust-dosing-according-to-liver-function-monitoring
   Google Scholar
• US Food and Drug Administration (FDA). FDA warns about serious liver injury with Ocaliva (Obeticholic acid) for rare chronic liver disease issued on. 2017 Sept 21 cited 2020 Jan 7 Available from: https://www.fda.gov/media/111167/download
   Google Scholar
• Sayiner M, Stepanova M, De Avila L, et al. Outcomes of liver transplant candidates with primary biliary cholangitis: the data from the scientific registry of transplant recipients. Dig Dis Sci. 2020;65:416–422.
   PubMed Web of Science ®Google Scholar
• Singal AK, Guturu P, Hmoud B, et al. Evolving frequency and outcomes of liver transplantation based on aetiology of liver disease. Transplantation. 2013;95:755–760.
   PubMed Web of Science ®Google Scholar
• Silveira MG, Talwalkar JA, Lindor KD, et al. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant. 2010;10:720–726.
   PubMed Web of Science ®Google Scholar
• Montano-Loza AJ, Hansen BE, Corpechot C, et al. Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival. Gastroenterology. 2019;156:96–107.
   PubMed Web of Science ®Google Scholar
• Bosch A, Dumortier J, Maucort-Boulch D, et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. J Hepatol. 2015;63:1449–1458.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chazouilleres O, Montano-Loza A, et al. Preventive administration of ursodeoxycholic acid after liver transplantation for primary biliary cholangitis prevents disease recurrence and prolongs graft survival. European Association for the Study of the Liver International Liver Congress; Vienna, Austria; Apr 10–14, 2019.
   Google Scholar
• Kuiper EM, Hansen BE, Lesterhuis W, et al. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis. Clin Res Hepatol Gastroenterol. 2011;35:29–33.
   PubMed Web of Science ®Google Scholar
• Pasha T, Heathcote J, Gabriel S, et al. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology. 1999;29:21–26.
   PubMed Web of Science ®Google Scholar
• Boberg KM, Wisloff T, Kjollesdal KS, et al. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment Pharmacol Ther. 2013;38:794–803.
   PubMed Web of Science ®Google Scholar
• Samur S, Klebanoff M, Banken R, et al. Long‐term clinical impact and cost‐effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology. 2017;65:920‐ 928.
   Web of Science ®Google Scholar
• Longworth L, Young T, Buxton MJ, et al. Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transpl. 2003;9:1295–1307.
   PubMed Web of Science ®Google Scholar
• Tome S, Wells JT, Said A, et al. Quality of life after liver transplantation. A systematic review. J Hepatol. 2008;48:567–577.
   PubMed Web of Science ®Google Scholar
• Silveira MG, Brunt EM, Heathcote J, et al. American association for the study of liver diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology. 2010;52:349‐ 359.
   PubMed Web of Science ®Google Scholar
• Nagano T, Yamamoto K, Matsumoto S, et al. Cytokine profile in the liver of primary biliary cirrhosis. J Clin Immunol. 1999;19:422‐427.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009;360:2544‐2555.
   PubMed Web of Science ®Google Scholar
• Harada K, Shimoda S, Sato Y, et al. Periductal interleukin‐17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol. 2009;157:261–270.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Yang GX, Zhang W, et al. Deletion of interleukin‐12p40 suppresses autoimmune cirrhosis in dnTGFβRII mice. Hepatology. 2009;50:1494‐1500.
   PubMedGoogle Scholar
• Dyson JK, Hirschfield GM, Adams DH, et al. Novel therapeutic targets in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol. 2015;12:147‐158.
   PubMed Web of Science ®Google Scholar
• PURIFI Study Group. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study. Hepatology. 2016;64(1):189–199.
   PubMed Web of Science ®Google Scholar
• Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6:517–526.
   PubMed Web of Science ®Google Scholar
• Shin DJ, Wang L. Bile acid-activated receptors: a review on FXR and other nuclear receptors. Handb Exp Pharmacol. 2019;256:51–72.
   PubMedGoogle Scholar
• Goldstein J, Cynthia L. Novel and emerging therapies for cholestatic liver diseases. Liver Int. 2018;38:1520–1535.
   PubMed Web of Science ®Google Scholar
• Deutschmann K, Reich M, Klindt C, et al. Bile acid receptors in the biliary tree: TGR5 in physiology and disease. BBA-Mol Basis Dis. 1864;1319-1325:2018.
   Google Scholar
• Banales JM, Saez E, Uriz M, et al. Upregulation of mir-506 leads to decreased CL-/HCO3-anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology. 2012;56(2):687–697.
   PubMed Web of Science ®Google Scholar
• Beuers U, Hohenester S, de Buy Wenniger LJ, et al. The biliary HCO (3) (-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology. 2010;52:1489–1496.
   PubMed Web of Science ®Google Scholar
• Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 2018;67:534–541.
   PubMed Web of Science ®Google Scholar
• Iwaisako K, Haimerl M, Paik YH, et al. protection from liver fibrosis by a peroxisome proliferative-activated receptor δ agonist. Proc Natl Acad Sci U S A. 2012;109(21):E1369–76.
   PubMed Web of Science ®Google Scholar
• Jones DE, Boudes PF, Swain MG, et al. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to Ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017;2:716–726.
   PubMed Web of Science ®Google Scholar
• Nozaki Y, Harada K, Sanzen T, et al. PPARγ ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis. Med Mol Morphol. 2013;46:153.
   PubMed Web of Science ®Google Scholar
• Chascsa DMH, Lindor KD. Emerging therapies for PBC. J Gastroenterol. 2020;55:261–272.
   PubMed Web of Science ®Google Scholar
• Grigorian AY, Mardini HE, Corpechot C, et al. C LevyFenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39:296–306.
   PubMed Web of Science ®Google Scholar
• Suraweera D, Rahal H, Jimenez M, et al. Treatment of primary biliary cholangitis non‐responders: a systematic review. Liver Int. 2017;37:1877‐ 1886.
   PubMed Web of Science ®Google Scholar
• Corpechot, Chazouillères O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378:2171–2181.
   PubMed Web of Science ®Google Scholar
• Genfit. Elafibranor in PBC. [cited 2020 Jan 24]. Available from: https://www.genfit.com/pipeline/elafibranor-in-pbc/
   Google Scholar
• Rautiainen H, Kärkkäinen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three‐year randomized trial. Hepatology. 2005;41:747‐ 752.
   PubMed Web of Science ®Google Scholar
• Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000;31:318‐ 323.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Kupcinkas L, Ott P, et al. Budesonide add-on therapy in PBC patients with an incomplete response to UDCA: phase 3 trial. European Association for the Study of the Liver International Liver Congress; Paris, France; Apr 11–15, 2018
   Google Scholar
• Schramm C, Hirschfield G, Mason AL, et al. Early assessment of safety and efficacy of Tropifexor, a potent non-bile acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing phase 2 study. European Association for the Study of the Liver International Liver Congress; Paris, France; Apr 11-15, 2018.
   Google Scholar
• Trauner M, Gulamhusein A, Hameed B, et al. The nonsteroidal farnesoid X receptor agonist Cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology. 2019;70:788–801.
   PubMed Web of Science ®Google Scholar
• Myers RP, Swain MG, Lee SS, et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol. 2013;108:933–941.
   PubMed Web of Science ®Google Scholar
• Liu CH, Yang G‐X, Johnson CR, et al. An open‐label study of abatacept in patients with primary biliary cholangitis with an incomplete biochemical response to ursodeoxycholic acid. Hepatology. 2017;66:160A‐ 160A.
   Web of Science ®Google Scholar
• Wunsch E, Raszeja-Wyszomirska J, Barbier O, et al. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. J Gastrointestin Liver Dis. 2018;27:273–279.
   PubMed Web of Science ®Google Scholar
• Ma H, Zeng M, Han Y, et al. A multicenter, randomized, double‐blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore). 2016;95:e5391.
   PubMed Web of Science ®Google Scholar
• Wunsch E, Milkiewicz M, Wasik U, et al. Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease. Sci Rep. 2015 Aug;5:13462–21.
   PubMed Web of Science ®Google Scholar
• Mayo MJ, Wigg AJ, Leggett BA, et al. NGM282 for Treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Commun. 2018;2:1037–1050.
   PubMed Web of Science ®Google Scholar
• Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966;50:323–332.
   PubMed Web of Science ®Google Scholar
• Rust C, Sauter GH, Oswald M, et al. Effect of cholestyramine on bile acid patterns and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest. 2000;30:135–139.
   PubMed Web of Science ®Google Scholar
• McRae CA, Prince MI, Hudson M, et al. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology. 2003;125:591–596.
   PubMed Web of Science ®Google Scholar
• Hegade VS, Kendrick SFW, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389(10074):1114–1123.
   PubMed Web of Science ®Google Scholar
• Al-Dury S, Wahlström A, Wahlin S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep. 2018;8:6658.
   PubMed Web of Science ®Google Scholar
• Jopson L, Khanna A, Howel D, et al. Rituximab is inefficient for treatment of fatigue in primary biliary cholangitis: a phase‐2 randomised controlled trial. Hepatology. 2019;70:1646‐ 1657.
   PubMedGoogle Scholar
• Pharmaprojects. [cited 2020 Feb 26]. Available from: https://citeline.informa.com/drugs/results
   Google Scholar